

Evaluation of Platelet-to-Lymphocyte Ratio in Predicting Early and Long Term Outcomes Following Acute Coronary Syndrome

M. Hajahmadipoor Rafsanjani (MD)¹, E. Mansouri (MD)^{*2}

1. Department of Cardiology, Iran University of Medical Sciences, Tehran, I.R.Iran

2. Hazrate Rasool Akram Hospital, Iran University of Medical Sciences, Tehran, I.R.Iran

J Babol Univ Med Sci; 22; 2020; PP: 355-363

Received: Nov 2nd 2019, Revised: Mar 2nd 2020, Accepted: Apr 11st 2020.

ABSTRACT

BACKGROUND AND OBJECTIVE: The platelet-to-lymphocyte ratio (PLR) might be an important and critical measure in evaluating and anticipating undesirable outcomes in patients with acute coronary syndrome (ACS). What was discussed in this study was systemic evaluation of the role of PLR in predicting adverse outcomes of ACS (including mortality and MACE) both in the short term and in the long term.

METHODS: In this systematic review, studies related to platelet counts, lymphocytes, acute coronary artery syndrome were searched in Medline, Web of knowledge, Google scholar, Scopus, and Cochrane databases. Finally, 15 related studies were reviewed, including 7 prospective studies and 8 retrospective studies.

FINDINGS: In a review of 15 articles, a total of 8304 patients in the group with low PLR and 5822 patients in the group with high PLR were considered. The increase in PLR can increase the risk of short-term and long-term mortality by 0.3 and 1.8 times, respectively.

CONCLUSION: Based on the results of this study, the increase in PLR can effectively predict early and long term adverse events in patients with ACS.

KEY WORDS: *Blood Platelets, Lymphocytes, Acute Coronary Syndrome.*

Please cite this article as follows:

Hajahmadipoor Rafsanjani M, Mansouri E. Evaluation of Platelet-to-Lymphocyte Ratio in Predicting Early and Long Term Outcomes Following Acute Coronary Syndrome. J Babol Univ Med Sci. 2020; 22: 355-63.

***Corresponding Author: E. Mansouri (MD)**

Address: Hazrate Rasool Akram Hospital, Niayesh Street, Satarkhan Avenue, Tehran, I.R.Iran

Tel: +98 21 64352658

E-mail: : esmaeil.mansouri61@gmail.com

Introduction

Despite development of therapeutic methods and diagnostic tools, cardiovascular disorders remain as a major leading cause of mortality and disability around the world. In this regard, the critical role of inflammatory processes in progression of atherosclerotic plaques and increasing the susceptibility to ischemic events has been clearly determined (1). In fact, accumulation of inflammatory cells along with adhesion and aggregation of platelets on plaques is the causative pathophysiology of coronary heart disease which mainly sourced from some genetic polymorphisms and variants (2-4).

In this regard, recent evidences have emphasized the major role of reducing plasma leukocytes count in predicting improper outcome in patients suffering coronary artery disease as well as congestive heart failure (5-7). In the cases of persistent inflammation, blood leukocyte count may reduce due to increase in lymphocytic apoptosis. In fact, leukocyte response to inflammatory processes is considerable. In addition, the progression of inflammation may lead to increased proliferation of megakaryocyte series as important components of thrombosis. Previous studies could demonstrate a close relationship between increase in platelet counts and poor coronary artery disease-related outcome (8-10).

In this regard, platelet to lymphocyte ratio has been recently identified as a prognostic marker for mortality and morbidity due to cardiac ischemic events, long-term patients' survival following acute coronary syndrome as well as need to revascularization (11-14). Moreover, a high value of platelet to lymphocyte ratio has been associated with the increased likelihood of in-hospital mortality in patients suffering from acute myocardial infarction (15-18). Recent studies have shown that increasing the platelet count may be a predictor of acute coronary syndrome. In some large trials, such as TIMI, abnormal platelet cells have been predictive of higher mortality, re-infarction, and heart failure within 30 days of ACS occurrence (19). However, some studies have not seen such a role in predicting the 60-day outcome of ACS (20).

Other parameters associated with platelet count may play a role in the development of adverse outcomes in ACS. In this regard, some platelet hyper reactivity based on collagen / ADP closure time indices predict cardiovascular events (21). Some studies have shown a significant relationship between platelet residual activity (platelet aggregation in response to arachidonic acid agonists, ADP, and PFA-100) and the

consequences of ACS (22, 23). The role of both platelet count (through platelet aggregation and vascular atheroma formation) and leukocyte count (through activation of inflammatory processes and injury to atherosclerotic plaque) in the development of cardiovascular events is quite clear. The aim of this study was to systematically review the role of the ratio of platelets to lymphocytes in predicting the outcomes of patients with acute coronary artery syndrome.

Methods

Search strategy: This study was performed according to established methods and in compliance with PRISMA-P (Preferred Reporting Items for Systematic review and Meta-Analysis) Protocols with the ethics code IR.IUMS.FMD.REC.1396.9411160016 (24). We searched online databases including Medline, Web of knowledge, Google scholar, Scopus, and Cochrane for all eligible studies in accordance with the considered keywords including: "acute coronary syndrome", "platelet", and "lymphocyte", "platelet to lymphocyte ratio", "outcome" and "mortality" since 2000. The studies were restricted to English language. Inclusion criteria were the relationship between platelet-to-lymphocyte ratio and clinical outcomes in patients with acute coronary artery syndrome. In the absence of clear and reproducible results in the study, non-English studies, lack of access to the full text of article copies, 10 articles were deleted (Figure 1).

Data abstraction was independently performed by two un-blinded reviewers on structure collection forms without divergences in data collection. The study quality was evaluated based on the following criteria: 1) the systematic review and meta-analysis based on the questions primarily described and formulated; 2) inclusion and exclusion criteria predefined in the studies as eligibility criteria; 3) searching the literature performed on a systematic and comprehensive approach; 4) to minimize the bias, the full texts of the articles were reviewed independently by two reviewers; 5) the quality of included studies was rated independently by the reviewers for appraising internal validity; 6) studies' characteristics and findings were comprehensively listed; 7) the publication and risk of bias were listed; and 8) heterogeneity was also assessed (25). The present study was conducted to determine the early and long-term odds of mortality and major adverse cardiac events (MACE) after acute coronary syndrome through determining Odds Ratio for determining this association.




Figure 1. Flowchart for the selection of studies for final analysis

Statistical analysis: Dichotomous variables are reported as proportions and percentages, and continuous variables as mean values. Binary outcomes from individual studies were to be combined by the Mantel-Hansel fixed effect model. The odds ratio (OR) and 95% confidence interval (CI) were used as summary statistics for the comparison of dichotomous variables. Cochran's Q test was used to determine the statistical heterogeneity of this study.

This test was complemented with the I^2 statistic, which quantifies the proportion of total variation across studies that is due to heterogeneity rather than chance. An I^2 value of 0-25% indicates insignificant heterogeneity, 26-50% low heterogeneity, 51-75% moderate heterogeneity and 76-100% high heterogeneity.

Publication bias was assessed by the rank correlation test and also confirmed by the funnel plot analysis. Reported values were two-tailed, and hypothesis testing results were considered statistically significant at $p=0.05$. Statistical analysis was performed using the Stata software (version 13.1, Stata Corp, College Station, TX, USA).

Results

In this study, 15 studies were evaluated which included 7 prospective studies and 8 retrospective studies (26-39). In these studies, the participants in the study were classified into low PLR and high PLR groups in terms of both short and long term outcomes. In total, 8304 patients in the low PLR group and 5822 in the high PLR group were considered. The mean age of patients in the two groups was 60.06 ± 2.84 years and 63.27 ± 3.17 years, respectively.

In a total of 15 studies, the population studied in 4 studies involving patients with UA, in one study included patients with NSTEMI and in 10 studies involving patients with STEMI. In summary, a wide range of cut-off values for PLR was considered for predicting ACS outcomes, reported in the range of 116 to 217. Only 11 studies followed the patients for a long time, and the follow-up period was between 6 and 60 months. In total, 8 studies were performed on in-hospital mortality, 10 studies on long-term mortality, 4 studies on in-hospital MACE and 6 studies on long-term MACE.

In assessing the relationship between the increase in PLR and the prediction of hospital mortality, we found that patients with high PLR were more likely to face hospital deaths than patients with low PLR with a relative risk of 3.08 (95%CI: 2.43 to 3.91). Studies regarding the relationship between high PLR and hospital mortality were found to be of acceptable homogeneity (homogeneity coefficient= 29.0, $p=0.196$) (Figure 2).

Moreover, the studies did not have a publication bias ($p=0.216$). In assessing the relationship between increased PLR and long-term mortality prediction, the increase in PLR in patients with ACS was associated with an increased risk for long-term death (relative risk: 1.83, 95% confidence interval: 1.62 to 2.8). In this regard, studies also had high degree of heterogeneity (homogeneity coefficient= 0.81, $p=0.001$). Moreover, the studies had publication bias ($p=0.039$) (Figure 2).

In total, 10 studies examined the relationship between high PLR and in-hospital MACE. In the analysis of these studies, the increase in PLR predicted the occurrence of in-hospital MACE with a relative risk of 2.52 (95% CI: 1.76 to 2.88). Studies also had high levels of heterogeneity (homogeneity coefficient equal to 67, $p=0.023$) (Figure 2). However, studies did not have a significant publication bias ($p=0.999$). Moreover, increased PLR was a strong predictor for

long-term MACE after ACS (relative risk= 1.86, 95%CI: 1.64 to 1.21). However, studies also had high levels of heterogeneity (homogeneity coefficient equal to 0.81, $p=0.001$). The studies did not have a significant publication bias ($p=0.255$) (Figure 2). In total, the

increase in PLR could increase the risk of short and long term mortality by 0.3 and 1.8 times, respectively. Furthermore, an increase in PLR increased the risk of occurrence of short-term and long-term MACE by 2.2 and 1.8 times, respectively.




Figure 2. Results of the meta-analysis of the relationship between increased PLR and the relative risk of mortality and short- and long-term MACE in patients with ACS

A: long-term mortality

B: in-hospital mortality

C: long-term cardiac complications

D: in-hospital cardiac complications

Table 1. Details of the studies systematically assessed

Author	Study type	Country	Comparison	Number	Age (year)	Male (%)	ACS	Cutoff/PLR	Intervention
Lee, 2018 (71)	PC	Australia	Low/high PLR	342/172	63/65	67/72	UA	137	PCI
Bressi, 2018 (72)	PC	Italy	Low/high PLR	314/157	66/69	84/67	STEMI	164	PCI
Zhou, 2017 (73)	RC	China	Low/high PLR	426/213	58/60	61/61	STEMI	171	PCI
Sun, 2017 (74)	RC	China	Low/high PLR	1470/1484	58/63	77/78	STEMI	163	PCI
Ayca, 2015 (75)	RC	Turkey	Low/high PLR	281/159	56/59	68/65	STEMI	137	PCI
Ozcan Cetin, 2015 (76)	PC	Turkey	Low/high PLR	1292/646	60/60	66/66	STEMI	148	PCI
Cho, 2015 (77)	RC	Korea	Low/high PLR	508/290	60/62	66/61	UA	128	PCI
Hudzik, 2015 (78)	RC	Poland	Low/high PLR	349/174	63/65	41/43	STEMI	124	PCI
Toprak, 2015 (79)	PC	Turkey	Low/high PLR	318/217	60/59	83/76	STEMI	217	PCI
Osadnik, 2015 (80)	RC	Poland	Low/high PLR	986/987	62/65	76/66	STEMI	121	PCI
Kurtul, 2014 (81)	PC	Turkey	Low/high PLR	521/495	58/65	76/67	UA	116	PCI
Oylumu, 2014 (82)	RC	Turkey	Low/high PLR	391/196	60/65	44/66	UA	127	PCI
Temiz, 2014 (83)	RC	Turkey	Low/high PLR	474/212	61/64	74/73	STEMI	144	PCI
Ugur, 2014 (84)	PC	Turkey	Low/high PLR	426/213	55/60	85/85	STEMI	175	PCI
Azab, 2012 (85)	PC	USA	Low/high PLR	206/207	61/68	74/61	NSTEMI	176	PCI

Table 2. Details of hospital and long-term consequences of ACS in various studies

Author	Follow-up	Comparison	Early mortality	Long-term mortality	Early MACE	Long-term MACE
Lee, 2018 (71)	60.0	Low/high PLR	-	5.0/15.0	-	-
Bressi, 2018 (72)	60.0	Low/high PLR	-	5.4/11.5	-	15.0/24.2
Zhou, 2017 (73)	42.0	Low/high PLR	-	-	-	17.3/34.2
Sun, 2017 (74)	81.6	Low/high PLR	-	13.3/18.7	-	12.2/17.2
Ayca, 2015 (75)	In-hospital	Low/high PLR	2.5/8.2	-	6.0/18.9	-
Ozcan Cetin, 2015 (76)	31.6	Low/high PLR	2.1/4.0	5.0/7.6	5.7/9.6	12.0/21.1
Cho, 2015 (77)	62.8	Low/high PLR	-	3.1/6.6	-	-
Hudzik, 2015 (78)	12.0	Low/high PLR	11.2/17.8	8.3/33.9	-	-
Toprak, 2015 (79)	24.0	Low/high PLR	2.0/14.0	8.0/25.0	7.0/22.0	11.0/38.0
Osadnik, 2015 (80)	37.0	Low/high PLR	-	9.6/11.0	-	-
Kurtul, 2014 (81)	In-hospital	Low/high PLR	2.7/8.3	-	-	-
Oylum, 2014 (82)	In-hospital	Low/high PLR	4.9/14.8	-	-	-
Temiz, 2014 (83)	In-hospital	Low/high PLR	5.9/12.7	-	-	-
Ugur, 2014 (84)	6.0	Low/high PLR	1.4/2.6	4.0/8.0	5.4/8.0	22.1/27.7
Azab, 2012 (85)	48.0	Low/high PLR	-	16.0/33.0	-	-

Discussion

The role of both platelet counts (through the process of adhesion and platelet aggregation and the formation of vascular atheroma) and the leukocyte counts (by activating inflammatory processes and injuring atherosclerotic plaque) in the development of cardiovascular events have been clearly revealed. In recent years, the PLR index has been considered as an important and critical measure in evaluating and anticipating undesirable outcomes in patients with inflammatory and ischemic diseases (such as cardiovascular diseases, cerebrovascular accidents, and cancers). What was discussed in this study was the systemic evaluation of the role of PLR in predicting adverse outcomes of ACS (including mortality and MACE) both in the short term and in the long term. In this regard, a systematic analysis of studies aimed at comparing the two groups of patients with ACS with low PLR and high PLR was conducted to calculate the relative risk of occurrence of mortality and MACE in patients with increased PLR. What we finally found in

this systematic analysis was that, first, increased PLR can increase the risk of short and long term mortality by 0.3 and 1.8 times, respectively. Second, an increase in PLR increases the risk of occurrence of short and long-term MACE by 2.2 and 1.8 times, respectively. Therefore, this index can be used as a prognostic parameter in predicting adverse outcomes in ACS patients. However, the studies were accompanied by some potential limitations. Firstly, the PLR cut-off points had a wide range in studies in such a way that these cut-off points varied from 116 to 217, which would make it difficult to take advantage of a specific cut-off points in predicting the outcomes in a clinical setting. Perhaps the use of averaged cut-off points can be exploited clinically, which requires more studies. On the other hand, due to the variety of sample sizes in studies, differences in the design of studies (prospective or retrospective) and significant differences during the follow up of patients, high heterogeneity was observed. In fact, heterogeneity in these studies is mainly

influenced by the nature of the study, the choice of criteria for entering and leaving the study, the length of follow-up of patients, and most importantly the number of patients enrolled in the study. Each of these indicators may have contributed to the increase in heterogeneity. As a result, in the results of various studies, the publication bias in studies (except studies based on the evaluation of long-term mortality) was significantly lower. In terms of definition, publication bias means achieving both positive and negative results in studies. Therefore, in our analysis, studies had high similarity regarding the value of high PLR in the prediction of hospital mortality as well as short and long-term MACE and thus the studies had coherence in the publication of the results related to the predictability of PLR. In total, there are several reasons for publication bias. First of all, writers are usually interested in the significant results of their work and to publish these results, which can cause some irresponsible results never to be sent to magazines. Secondly, some editors and reviewers of journals tend to publish more positive and significant results in their journals because they have less

significant readers. In sum, what can be deduced from the heterogeneity of the system and the high publication bias is that, first, studies should be carried out in different societies, taking into account racial and geographical differences, and second, the evaluation and analysis of articles published in journals with the above profiles is preferable.

Increased PLR in predicting early and long-term outcomes (including mortality and MACE) in patients with ACS has a high prognostic value. In this regard, increasing PLR increases the risk of short-term and long-term mortality by 0.3 and 1.8 times, respectively. Also, increasing PLR increases the risk of short-term and long-term MACE by 2.2 and 1.8 times, respectively.

Acknowledgment

We would like to thank the Faculty of Medicine and Vice Chancellor for Research and Technology of Iran University of Medical Sciences for supporting this research.

References

1. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. *N Engl J Med*. 2005;352(16):1685-95.
2. Han Y-C, Yang T-H, Kim D-I, Jin H-Y, Chung S-R, Seo J-S, et al. Neutrophil to Lymphocyte Ratio Predicts Long-Term Clinical Outcomes in Patients with ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. *Korean Circ J*. 2013;43(2):93-9.
3. Tamhane UU, Aneja S, Montgomery D, Rogers E-K, Eagle KA, Gurm HS. Association between admission neutrophil to lymphocyte ratio and outcomes in patients with acute coronary syndrome. *Am J Cardiol*. 2008;102(6):653-7.
4. Duffy BK, Gurm HS, Rajagopal V, Gupta R, Ellis SG, Bhatt DL. Usefulness of an elevated neutrophil to lymphocyte ratio in predicting long-term mortality after percutaneous coronary intervention. *Am J Cardiol*. 2006;97(7):993-6.
5. Acanfora D, Gheorghiade M, Trojano L, Furgi G, Pasini E, Picone C, et al. Relative lymphocyte count: a prognostic indicator of mortality in elderly patients with congestive heart failure. *Am Heart J*. 2001;142(1):167-73.
6. Ommen SR, Gibbons RJ, Hodge DO, Thomson SP. Usefulness of the lymphocyte concentration as a prognostic marker in coronary artery disease. *Am J Cardiol*. 1997;79(6):812-4.
7. Zouridakis EG, Garcia-Moll X, Kaski JC. Usefulness of the blood lymphocyte count in predicting recurrent instability and death in patients with unstable angina pectoris. *Am J Cardiol*. 2000;86(4):449-51.
8. Nikolsky E, Grines CL, Cox DA, Garcia E, Tchong JE, Sadeghi M, et al. Impact of baseline platelet count in patients undergoing primary percutaneous coronary intervention in acute myocardial infarction (from the CADILLAC trial). *Am J Cardiol*. 2007;99(8):1055-61.
9. Iijima R, Ndrepepa G, Mehilli J, Bruskin O, Schulz S, Schomig A, et al. Relationship between platelet count and 30-day clinical outcomes after percutaneous coronary interventions. Pooled analysis of four ISAR trials. *Thromb Haemost*. 2007;98(4):852-7.
10. Thaulow E, Erikssen J, Sandvik L, Stormorken H, Cohn PF. Blood platelet count and function are related to total and cardiovascular death in apparently healthy men. *Circulation*. 1991;84(2):613-7.
11. Smith RA, Ghaneh P, Sutton R, Raraty M, Campbell F, Neoptolemos JP. Prognosis of resected ampullary adenocarcinoma by preoperative serum CA19-9 levels and platelet-lymphocyte ratio. *J Gastrointest Surg*. 2008;12(8):1422-8.
12. Smith RA, Bosonnet L, Raraty M, Sutton R, Neoptolemos JP, Campbell F, et al. Preoperative platelet-lymphocyte ratio is an independent significant prognostic marker in resected pancreatic ductal adenocarcinoma. *Am J Surg*. 2009;197(4):466-72.
13. Proctor MJ, Morrison DS, Talwar D, Balmer SM, Fletcher CD, O'Reilly DS, et al. A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study. *Eur J Cancer*. 2011;47(17):2633-41.
14. Gary T, Pichler M, Belaj K, Hafner F, Gerger A, Froehlich H, et al. Platelet-to-lymphocyte ratio: a novel marker for critical limb ischemia in peripheral arterial occlusive disease patients. *PLoS One*. 2013;8(7):e67688.
15. Azab B, Shah N, Akerman M, McGinn JT. Value of platelet/lymphocyte ratio as a predictor of all-cause mortality after non-ST-elevation myocardial infarction. *J Thromb Thrombolysis*. 2012;34(3):326-34.
16. Yıldız A, Yuksel M, Oylumlu M, Polat N, Akyuz A, Acet H, et al. The Utility of the platelet-lymphocyte ratio for predicting no reflow in patients with ST-segment elevation myocardial infarction. *Clin Appl Thromb Hemost*. 2015;21(3):223-8.
17. Oylumlu M, Yıldız A, Oylumlu M, Yuksel M, Polat N, Bilik MZ, et al. Platelet-to-lymphocyte ratio is a predictor of in-hospital mortality patients with acute coronary syndrome. *Anatol J Cardiol*. 2015;15(4):277-83.
18. Temiz A, Gazi E, Gungor O, Barutcu A, Altun B, Bekler A, et al. Platelet/lymphocyte ratio and risk of in-hospital mortality in patients with ST-elevated myocardial infarction. *Med Sci Monit*. 2014;20:660-5.
19. Ly HQ, Kirtane AJ, Murphy SA, Buross J, Cannon CP, Braunwald E, et al. Association of platelet counts on presentation and clinical outcomes in ST-elevation myocardial infarction (from the TIMI Trials). *Am J Cardiol*. 2006;98(1):1-5.
20. Mueller C, Neumann F-J, Hochholzer W, Trenk D, Zeller T, Perruchoud AP, et al. The impact of platelet count on mortality in unstable angina/non-ST-segment elevation myocardial infarction. *Am Heart J*. 2006;151(6):1214.e1-7.
21. Christie DJ, Kottke-Marchant K, Gorman RT. Hypersensitivity of platelets to adenosine diphosphate in patients with stable cardiovascular disease predicts major adverse events despite antiplatelet therapy. *Platelets*. 2008;19(2):104-10.

22. Marcucci R, Gori AM, Panicia R, Gigliola C, Buonamicia P, Antonucci D, et al. Residual platelet reactivity is associated with clinical and laboratory characteristics in patients with ischemic heart disease undergoing PCI on dual antiplatelet therapy. *Atherosclerosis* 2007;195(1):e217-e23.
23. Frere C, Cuisset T, Quilici J, Camoin L, Carvajal J, Morange PE, et al. ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome. *Thromb Haemost.* 2007;98(4):838-43.
24. Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. *BMJ.* 2015;350:g7647.
25. Zeng X, Zhang Y, Kwong JS, Zhang C, Li S, Sun F, et al. The methodological quality assessment tools for preclinical and clinical studies, systematic review and meta-analysis, and clinical practice guideline: a systematic review. *J Evid Based Med.* 2015;8(1):2-10.
26. Lee YS, Baradi A, Peverelle M, Sultani R, Adams H, Garlick J, et al. Usefulness of Platelet-to-Lymphocyte Ratio to Predict Long-Term All-Cause Mortality in Patients at High Risk of Coronary Artery Disease Who Underwent Coronary Angiography. *Am J Cardiol.* 2018;121(9):1021-6.
27. Bressi E, Mangiacapra F, Ricottini E, Cavallari I, Colaioni I, Di Gioia G, et al. Impact of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio on 5-Year Clinical Outcomes of Patients with Stable Coronary Artery Disease Undergoing Elective Percutaneous Coronary Intervention. *J Cardiovasc Transl Res.* 2018;11(6):517-23.
28. Zhou D, Wang G, Fan Y, Wan Z, Liu X. Platelet to lymphocyte ratio is associated with the severity of coronary artery disease and clinical outcomes of percutaneous coronary intervention in the Chinese Han population. *Exp Ther Med.* 2017;13(2):731-8.
29. Sun X-P, Li J, Zhu W-W, Li D-B, Chen H, Li H-W, et al. Impact of Platelet-to-Lymphocyte Ratio on Clinical Outcomes in Patients With ST-Segment Elevation Myocardial Infarction. *Angiology.* 2017;68(4):346-53.
30. Ayça B, Akin F, Çelik Ö, Yüksel Y, Öztürk D, Tekiner F, et al. Platelet to lymphocyte ratio as a prognostic marker in primary percutaneous coronary intervention. *Platelets.* 2015;26(7):638-44.
31. Ozcan Cetin EH, Cetin MS, Aras D, Topaloglu S, Temizhan A, Kisacik HL, et al. Platelet to Lymphocyte Ratio as a Prognostic Marker of In-Hospital and Long-Term Major Adverse Cardiovascular Events in ST-Segment Elevation Myocardial Infarction. *Angiology.* 2016;67(4):336-45.
32. Cho KI, Ann SH, Singh GB, Her A-Y, Shin E-S. Combined Usefulness of the Platelet-to-Lymphocyte Ratio and the Neutrophil-to-Lymphocyte Ratio in Predicting the Long-Term Adverse Events in Patients Who Have Undergone Percutaneous Coronary Intervention with a Drug-Eluting Stent. *PLoS One.* 2015;10(7):e0133934.
33. Hudzik B, Szkodziński J, Gorol J, Niedziela J, Lekston A, Gasior M, et al. Platelet-to-lymphocyte ratio is a marker of poor prognosis in patients with diabetes mellitus and ST-elevation myocardial infarction. *Biomark Med.* 2015;9(3):199-207.
34. Toprak C, Tabakci MM, Simsek Z, Arslantas U, Durmus H, Ocal L, et al. Platelet/lymphocyte ratio was associated with impaired myocardial perfusion and both in-hospital and long-term adverse outcome in patients with ST-segment elevation acute myocardial infarction undergoing primary coronary intervention. *Postepy Kardiol Interwencyjne.* 2015;11(4):288-97.
35. Osadnik T, Wasilewski J, Lekston A, Strzelczyk J, Kurek A, Gonera M, et al. The platelet-to-lymphocyte ratio as a predictor of all-cause mortality in patients with coronary artery disease undergoing elective percutaneous coronary intervention and stent implantation. *J Saudi Heart Assoc.* 2015;27(3):144-51.
36. Kurtul A, Murat SN, Yarlioglu M, Duran M, Ergun G, Acikgoz SK, et al. Association of platelet-to-lymphocyte ratio with severity and complexity of coronary artery disease in patients with acute coronary syndromes. *Am J Cardiol.* 2014;114(7):972-8.
37. Oylumlu M, Yıldız A, Oylumlu M, Yüksel M, Polat N, Bilik MZ, et al. Platelet-to-lymphocyte ratio is a predictor of in-hospital mortality patients with acute coronary syndrome. *Anatol J Cardiol.* 2015;15(4):277-83.
38. Temiz A, Gazi E, Güngör Ö, Barutçu A, Altun B, Bekler A, et al. Platelet/lymphocyte ratio and risk of in-hospital mortality in patients with ST-elevated myocardial infarction. *Med Sci Monit.* 2014;20:660-5.
39. Ugur M, Gul M, Bozbay M, Cicek G, Uyarel H, Koroglu B, et al. The relationship between platelet to lymphocyte ratio and the clinical outcomes in ST elevation myocardial infarction underwent primary coronary intervention. *Blood Coagul Fibrinolysis.* 2014;25(8):806-11.